BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23446736)

  • 41. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation.
    Truitt RL; Atasoylu AA
    Blood; 1991 Jun; 77(11):2515-23. PubMed ID: 2039833
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
    Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
    Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Granzyme B-mediated damage of CD8+ T cells impairs graft-versus-tumor effect.
    Bian G; Ding X; Leigh ND; Tang Y; Capitano ML; Qiu J; McCarthy PL; Liu H; Cao X
    J Immunol; 2013 Feb; 190(3):1341-50. PubMed ID: 23264653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms.
    Hsieh MH; Patterson AE; Korngold R
    Biol Blood Marrow Transplant; 2000; 6(3):231-40. PubMed ID: 10871148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.
    Chakraverty R; Eom HS; Sachs J; Buchli J; Cotter P; Hsu R; Zhao G; Sykes M
    Blood; 2006 Sep; 108(6):2106-13. PubMed ID: 16757687
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice.
    Zeis M; Uharek L; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N
    Br J Haematol; 1997 Mar; 96(4):757-61. PubMed ID: 9074419
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
    Weiss L; Nusair S; Reich S; Sidi H; Slavin S
    Cancer Immunol Immunother; 1996 Oct; 43(2):103-8. PubMed ID: 8954144
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.
    Boyer MW; Vallera DA; Taylor PA; Gray GS; Katsanis E; Gorden K; Orchard PJ; Blazar BR
    Blood; 1997 May; 89(9):3477-85. PubMed ID: 9129056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses.
    Reddy P; Maeda Y; Liu C; Krijanovski OI; Korngold R; Ferrara JL
    Nat Med; 2005 Nov; 11(11):1244-9. PubMed ID: 16227991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation.
    Li M; Sun K; Redelman D; Welniak LA; Murphy WJ
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):739-50. PubMed ID: 20338256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose.
    Bachar-Lustig E; Reich-Zeliger S; Reisner Y
    Blood; 2003 Sep; 102(6):1943-50. PubMed ID: 12775573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.
    Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Type I-IFNs control GVHD and GVL responses after transplantation.
    Robb RJ; Kreijveld E; Kuns RD; Wilson YA; Olver SD; Don AL; Raffelt NC; De Weerd NA; Lineburg KE; Varelias A; Markey KA; Koyama M; Clouston AD; Hertzog PJ; Macdonald KP; Hill GR
    Blood; 2011 Sep; 118(12):3399-409. PubMed ID: 21719602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.